You are here

NOVEL ADENOSINE A2A AGONISTS IN RENAL TISSUE PROTECTION

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44DK058413-02A1
Agency Tracking Number: DK058413
Amount: $818,282.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
ADENOSINE THERAPEUTICS, LLC 300 PRESTON AVE, 5TH FL
CHARLOTTESVILLE, VA 22902
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 RAY OLSSON
 (603) 396-1129
 RDT@ADENOS.COM
Business Contact
 MARY NADLER
Phone: (434) 220-9400
Email: MNADLER@ADENOSINETHERAPEUTICS.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): The development of new treatments for the
effective reduction of renal injury associated with acute renal failure and
kidney transplantation will have a great impact on health care delivery to
patients with renal disease. Acute ischemic renal failure affects 5 percent of
hospitalized patients and has a mortality rate approaching 50 percent. At
present, dialysis is the only FDA-approved treatment for acute renal failure.
lschemia-reperfusion injury at the time of kidney transplantation causes
delayed graft function and shortens graft survival. The long-term goal of this
project is to evaluate the ability of a proprietary A2A adenosine receptor
(A2A-AR) agonist, ATL146e to reduce renal injury in humans. The current
proposal aims at completing the preclinical characterization of ATL 146e, a
potent and selective A2A-AR agonist that has optimum pharmacological
characteristics. Aim I addresses FDA requirements for toxicology,
pharmacokinetics and metabolism. Aim 2 devises more efficient synthetic methods
so that scale-up can support expanded preclinical studies and guide synthesis
by certified Good Manufacturing Practices to support human studies. Aim 3
develops an in vivo assay for ATL 146e-mediated anti-inflammatory activity. Aim
4 tests the efficacy of ATL 146e in reducing injury in model of acute
ischemia-reperfusion associated with kidney transplantation.

PROPOSED COMMERCIAL APPLICATION: The incidence of azotemia, which includes all cases of acute renal failure (volume depletion, obstruction and intrinsic causes such as ischemia and toxins), was estimated in 1997 to be 275,000 patients per year. Additionally, it is estimated that all cases of azotemia are increasing at rate of 16,000 patients/year. The goal of this research is to develop a pharmaceutical product which will address this unmet medical need. All of the specific aims in this project are required by the FDA and ICH for drug development.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government